Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F

AIDS Research and Human Retroviruses

Volumn 27, Issue 8, 2011, Pages 889-901

  Revilla, Ana ^a   Delgado, Elena ^a   Christian, Elizabeth C ^b   Dalrymple, Justin ^b   Vega, Yolanda ^a   Carrera, Cristina ^a   González Galeano, María ^a   Ocampo, Antonio ^c   De Castro, Rafael Ojea ^d   Lezaún, María J ^e   Rodríguez, Raúl ^f   Mariño, Ana ^g   Ordóñez, Patricia ^g   Cilla, Gustavo ^h   Cisterna, Ramón ⁱ   Santamaría, Juan M ⁱ   Prieto, Santiago ^j   Rakhmanova, Aza ^k   Vinogradova, Anna ^l   Ríos, Maritza ^m   Pérez Álvarez, Lucía ^a   Nájera, Rafael ^a   Montefiori, David C ⁿ   Seaman, Michael S ^b   Thomson, Michael M ^a   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Complejo Hospitalario Xeral Cíes ^*  (Spain)

^d HOSPITAL MONTECELO   (Spain)

^e HOSPITAL TXAGORRITXU   (Spain)

^f Complejo Hospitalario Santa María Madre ^*  (Spain)

^g Universidad de La Coruña   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL DE BASURTO   (Spain)

^j HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^k Botkin's Infectious Diseases Hospital   (Russian Federation)

^l St Petersburg AIDS Center   (Russian Federation)

^m INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; SOLUBLE CD4 ANTIGEN; VIRUS RNA;

ANTIGEN BINDING; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPITOPE MAPPING; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ASSEMBLY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CELL LINE; CLONING, MOLECULAR; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; NEUTRALIZATION TESTS; PHYLOGENY; PLASMIDS; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; TRANSFECTION;

EID: 80051516348     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0177     Document Type: Article

References (93)

1. Thomson MM, Pérez-Álvarez L, and Nájera R: Molecular epidemiology of HIV-genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002;2:461-471. (Pubitemid 34826851)
2. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360. (Pubitemid 34734202)
3. HIV Sequence Database: Available at http://www.hiv.lanl gov.
4. Thomson MM and Ná jera R: Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: An update. AIDS Rev 2005;7:210-224. (Pubitemid 43115953)
5. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-W23. (Pubitemid 44611051)
6. Mascola JR and Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010;28:413-444.
7. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5:204-210. (Pubitemid 29068528)
8. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210. (Pubitemid 30082367)
9. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206. (Pubitemid 30082366)
10. Mascola JR, Louwagie J, McCutchan FE, et al.: Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J Infect Dis 1994;169:48-54.
11. Binley JM, Wrin T, Korber B, et al.: Comprehensive crossclade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004;78:13232-13252. (Pubitemid 39507829)
12. Li M, Salazar-González JF, Derdeyn CA, et al.: Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006;80:11776-11790. (Pubitemid 44788890)
13. Brown BK, Wieczorek L, Sanders-Buell E, et al.: Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008;375:529-538.
14. Blish CA, Jalalian-Lechak Z, Rainwater S, Nguyen MA, Dogan OC, and Overbaugh J: Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol 2009;83:7783-7788.
15. van Gils MJ, Edo-Matas D, Schweighardt B, Wrin T, and Schuitemaker H: High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: Evidence for subtype-specific rather than strain-specific neutralizing activity. J Gen Virol 2010;91:250-258.
16. Seaman MS, Janes H, Hawkins N, et al.: Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010;84:1439-1452.
17. Mascola JR, D'Souza P, Gilbert P, et al.: Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005;79:10103-10107. (Pubitemid 41098551)
18. Polonis VR, Schuitemaker H, Bunnik EM, Brown BK, and Scarlatti G: Impact of host cell variation on the neutralization of HIV-1 in vitro. Curr Opin HIV AIDS 2009;4:400-407.
19. Li M, Gao F, Mascola JR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79:10108-10125. (Pubitemid 41098552)
20. Blish CA, Nedellec R, Mandaliya K, Mosier DE, and Overbaugh J: HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007;21:693-702. (Pubitemid 46568626)
21. Schweighardt B, Liu Y, Huang W, et al.: Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 2007;46:1-11. (Pubitemid 47507428)
22. Gray ES, Meyers T, Gray G, Montefiori DC, and Morris L: Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 2006;3:e255.
23. Kulkarni SS, Lapedes A, Tang H, et al.: Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 2009;385:505-520.
24. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, et al.: Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01-AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect 2009;11:334-343.
25. Nie J, Zhang C, Liu W, et al.: Genotypic and phenotypic characterization of HIV-1 CRF01-AE env molecular clones from infections in China. J Acquir Immune Defic Syndr 2010;53:440-450.
26. Gao F, Morrison SG, Robertson DL, et al.: Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996;70:1651-1667. (Pubitemid 26062925)
27. Agwale SM, Zeh C, Robbins KE, et al.: Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine 2002;20:2131-2139. (Pubitemid 34327786)
28. Peeters M, Esu-Williams E, Vergne L, et al.: Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses 2000;16:315-325. (Pubitemid 30132086)
29. Entonu PE and Agwale SM: A review of the epidemiology, prevention and treatment of human immunodeficiency virus infection in Nigeria. Braz J Infect Dis 2007;11:579-590. (Pubitemid 351436186)
30. Esteves A, Parreira R, Venenno T, et al.: Molecular epidemiology of HIV type 1 infection in Portugal: High prevalence of non-B subtypes. AIDS Res Hum Retroviruses 2002;18:313-325. (Pubitemid 34253130)
31. Niama FR, Toure-Kane C, Vidal N, et al.: HIV-1 subtypes and recombinants in the Republic of Congo. Infect Genet Evol 2006;6:337-343. (Pubitemid 43964477)
32. Thomson MM, Delgado E, Manjón N, et al.: HIV-1 genetic diversity in Galicia Spain: BG intersubtype recombinant viruses are circulating among injecting drug users. AIDS 2001;15:509-516. (Pubitemid 32207571)
33. Delgado E, Thomson MM, Villahermosa ML, et al.: Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr 2002;29:536-543. (Pubitemid 34456347)
34. Pérez L, Thomson MM, Bleda MJ, et al.: HIV Type 1 molecular epidemiology in Cuba: High genetic diversity, frequent mosaicism, and recent expansion of BG intersubtype recombinant forms. AIDS Res Hum Retroviruses 2006;22:724-733. (Pubitemid 44734998)
35. Sierra M, Thomson MM, Posada D, et al.: Identification of 3 phylogenetically related HIV-1 BG intersubtype circulating recombinant forms in Cuba. J Acquir Immune Defic Syndr 2007;45:151-160. (Pubitemid 46869807)
36. Apetrei C, Necula A, Holm-Hansen C, et al.: HIV-1 diversity in Romania. AIDS 1998;12:1079-1085. (Pubitemid 28276976)
37. Triques K, Bourgeois A, Saragosti S, et al.: High diversity of HIV-1 subtype F strains in Central Africa. Virology 1999;259:99-109. (Pubitemid 29391759)
38. Thomson MM, Sierra M, Tanuri A, et al.: Analysis of near full-length genome sequences of HIV type 1 BF intersubtype recombinant viruses from Brazil reveals their independent origins and their lack of relationship to CRF12-BF. AIDS Res Hum Retroviruses 2004;20:1126-1133. (Pubitemid 39392018)
39. Sanabani S, Kleine NW, Kalmar EM, Diaz RS, Janini LM, and Sabino EC: Analysis of the near full length genomes of HIV-1 subtypes B, F and BF recombinant from a cohort of 14 patients in Sao Paulo, Brazil. Infect Genet Evol 2006;6:368-377. (Pubitemid 43964479)
40. Thomson MM, Villahermosa ML, Vázquez de Parga E, et al.: Widespread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina. AIDS 2000;14:897-899. (Pubitemid 30303471)
41. Thomson MM, Delgado E, Herrero I, et al.: Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near fulllength genome sequences. J Gen Virol 2002;83:107-119. (Pubitemid 34030815)
42. Carr JK, Avila M, Gomez CM., et al.: Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS 2001;15:F41-F47. (Pubitemid 32980632)
43. Ríos M, Delgado E, Pérez-Álvarez L, et al.: Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J Med Virol 2007;79:647-656. (Pubitemid 46709357)
44. Delgado E, Rios M, Fernández J, Pérez-Álvarez L, Nájera R, and Thomson MM: Identification of a new HIV-1 BF intersubtype circulating recombinant form (CRF44-BF) in Chile. AIDS Res Hum Retroviruses 2010;26:821-826.
45. Brownstein MJ, Carpten JD, and Smith JR: Modulation of non-templated nucleotide addition by Taq DNA polymerase: Primer modifications that facilitate genotyping. Biotechniques 1996;20:1004-1010. (Pubitemid 126509230)
46. Salazar-González JF, Bailes E, Pham KT, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008;82:3952-3970. (Pubitemid 351521232)
47. Wei X, Decker JM, Liu H, et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905. (Pubitemid 34535213)
48. Katoh K, Kuma K, Toh H, and Miyata T: MAFFT version 5: Improvement in accuracy of multiple sequence alignment. Nucleic Acids Res 2005;33:511-518. (Pubitemid 40360980)
49. Stamatakis A, Hoover P, and Rougemont J: A rapid bootstrap algorithm for the RAxML Web servers. Syst Biol 2008;57:758-771.
50. Lole KS, Bollinger RC, Paranjape RS, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160. (Pubitemid 28565356)
51. Montefiori DC: Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2004;Chapter 12: Unit 12.11.
52. Cecilia D, KewalRamani VN, O'Leary J, et al.: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998;72: 6988-6996. (Pubitemid 28377825)
53. Vodros D, Tscherning-Casper C, Navea L, Schols D, De Clercq E, and Fenyo EM: Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay. Virology 2001;291:1-11. (Pubitemid 34062195)
54. Briggs DR, Tuttle DL, Sleasman JW, and Goodenow MM: Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000;14:2937-2939. (Pubitemid 32042758)
55. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotypeassociated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
56. Jensen MA, Li FS, van't Wout AB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77:13376-13388. (Pubitemid 37494331)
57. Sing T, Low AJ, Beerenwinkel N, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007;12:1097-1106. (Pubitemid 350114990)
58. Fernández-García A, Cuevas MT, Vinogradova A, et al.: Near full-length genome characterization of a newly identified HIV type 1 subtype F variant circulating in St. Petersburg, Russia. AIDS Res Hum Retroviruses 2009;25: 1187-1191.
59. Buchacher A, Predl R, Strutzenberger K, et al.: Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369. (Pubitemid 24141210)
60. Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, and Lerner RA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-10137. (Pubitemid 21915789)
61. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027. (Pubitemid 24373715)
62. Saphire EO, Stanfield RL, Crispin MD, et al.: Crystal structure of an intact human IgG: Antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design. Adv Exp Med Biol 2003;535:55-66. (Pubitemid 38130241)
63. Mo H, Stamatatos L, Ip JE, et al.: Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. J Virol 1997;71:6869-6874. (Pubitemid 27355348)
64. Pantophlet R, Ollmann SE, Poignard P, Parren PW, Wilson IA, and Burton DR: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003;77:642-658. (Pubitemid 36005001)
65. Duenas-Decamp MJ, Peters P, Burton D, and Clapham PR: Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J Virol 2008;82:5807-5814. (Pubitemid 351822255)
66. Wu S, Zhou T, O'Dell S, Wyatt RT, Kwong PD, and Mascola JR: Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody b12 that effectively targets the site of CD4 attachment. J Virol 2010;83:10892-10906.
67. Scanlan CN, Pantophlet R, Wormald MR, et al.: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1?2 mannose residues on the outer face of gp120. J Virol 2002;76:7306-7321.
68. Sanders RW, Venturi M, Schiffner L, et al.: The mannosedependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002;76:7293-7305.
69. Muster T, Steindl F, Purtscher M, et al.: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647. (Pubitemid 23309131)
70. Tian Y, Ramesh CV, Ma X, et al.: Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: Effects of side-chain and backbone modifications and conformational constraints. J Pept Res 2002;59:264-276. (Pubitemid 34539065)
71. Zwick MB, Jensen R, Church S, et al.: Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membraneproximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005;79:1252-1261. (Pubitemid 40053907)
72. Zwick MB, Labrijn AF, Wang M, et al.: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-10905. (Pubitemid 33034579)
73. Payan C, Dupre T, and Belec L: Detection of hepatitis C virus RNA by a reliable, optimized single-step reverse transcription polymerase chain reaction. Res Virol 1995;146: 363-370.
74. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-289.
75. Wu X, Yang Z-Y, Li Y, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329:856-861.
76. Bures R, Morris L, Williamson C, et al.: Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 2002;76:2233-2244. (Pubitemid 34150691)
77. Zhu T, Korber BT, Nahmias AJ, et al.: An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998;391:594-597. (Pubitemid 28157602)
78. Tscherning C, Alaeus A, Fredriksson R, et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998;241:181-188. (Pubitemid 28384191)
79. Abebe A, Demissie D, Goudsmit J, et al.: HIV-1 subtype C syncytium-and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999;13:1305-1311. (Pubitemid 29408444)
80. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, and Fenyo EM: Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999;15: 647-653. (Pubitemid 29205668)
81. Esbjornsson J, Mansson F, Martínez-Arias W, et al.: Frequent CXCR4 tropism of HIV-1 subtype A and CRF02-AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology 2010;7:23.
82. Tebit DM, Zekeng L, Kaptue L, Salminen M, Krausslich HG, and Herchenroder O: Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retroviruses 2002;18:39-48. (Pubitemid 34133027)
83. Zhong P, Burda S, Konings F, et al.: Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: Further evidence of broad HIV type 1 genetic diversity. AIDS Res Hum Retroviruses 2003;19:1167-1178. (Pubitemid 38037388)
84. Brandful JA, Coetzer ME, Cilliers T, et al.: Phenotypic characterization of HIV type 1 isolates from Ghana. AIDS Res Hum Retroviruses 2007;23:144-152. (Pubitemid 46214183)
85. Pérez-Álvarez L, Muñoz M, Delgado E, et al.: Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain. J Med Virol 2006;78:1520-1528. (Pubitemid 44672492)
86. Fernández-García A, Cuevas MT, Muñoz-Nieto M, et al.: Development of a panel of well-characterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. AIDS Res Hum Retroviruses 2009;25:93-102.
87. Cuevas MT, Fernández-García A, Pinilla M, et al.: Biological and genetic characterization of HIV-1 subtype B and nonsubtype B transmitted viruses: Usefulness for vaccine candidate assessment. AIDS Res Human Retroviruses 2010;26: 1019-1025.
88. Leitner T, Korovina G, Marquina S, Smolskaya T, and Albert J: Molecular epidemiology and MT-2 cell tropism of Russian HIV type 1 variant. AIDS Res Hum Retroviruses 1996;12:1595-1603. (Pubitemid 26423240)
89. Holm-Hansen C, Grothues D, Rustad S, Røsok B, Pascu FR, and Asjö B: Characterization of HIV type 1 from Romanian children: Lack of correlation between V3 loop amino acid sequence and syncytium formation in MT-2 cells. AIDS Res Hum Retroviruses 1995;11:597-603.
90. Holm-Hansen C, Baan E, Asjö B, Pascu FR, Goudsmit J, and De Jong JJ: Determinants form syncytium-inducing phenotype of HIV-1 subtype F isolates are located in the V3 region. AIDS Res Hum Retroviruses 2000;16:867-870. (Pubitemid 30399606)
91. Tscherning-Casper C, Vodros D, Menu E, et al.: Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. European Network for In Utero Transmission of HIV-1. J Acquir Immune Defic Syndr 2000;24:1-9. (Pubitemid 30447800)
92. Ragupathy V, Zhao J, Wang X, et al.: Comparative analysis of cell culture and prediction algorithms for phenotyping of genetically diverse HIV-1 strains from Cameroon. AIDS Res Ther 2009;6:27.
93. Garrido C, Roulet V, Chueca N, et al.: Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008;46:887-891. (Pubitemid 351379974)